Prognostic value of serum NLR, PLR, P53, K67 level in lymph node metastasis of early gastric cancer

血清中性粒细胞/淋巴细胞比值(NLR)、血小板/淋巴细胞比值(PLR)、P53、K67水平在早期胃癌淋巴结转移中的预后价值

阅读:1

Abstract

BACKGROUND: To explore the predictive value of relevant detection indexes and pathological serum NLR, PLR, P53, and K67 levels in lymph node metastasis (LNM) in patients with early gastric cancer (EGC) after radical surgery. METHODS: Clinical data of EGC patients (297 cases, all of whom underwent radical gastrectomy for gastric cancer) admitted to Sichuan Integrative Medicine Hospital from March 2019 to March 2024 were retrospectively included. The clinical data and pathological results were recorded and compared, and the related predictive factors were analysed. RESULTS: There were 43 cases (14.48%) of postoperative LNM among the 297 EGC patients. The average number of lymph nodes detected in the LNM (-) group was 28.35 ± 8.23, which was lower than in the LNM (+) group (33 ± 15), *P* < 0.01. Binary multivariate logistic regression analysis identified the following as significant predictors of postoperative LNM in EGC patients: tumour size (OR: 2.582, 95% CI: 1.205-5.534), depth of invasion (OR: 2.953, 95% CI: 1.327-6.573), vascular invasion (OR: 2.724, 95% CI: 1.241-5.976), neuroaggression (OR: 2.681, 95% CI: 1.139-6.311), differentiation type (OR: 2.426, 95% CI: 1.140-5.119), and P53 (OR: 3.133, 95% CI: 1.183-8.301), P<0.05. The area under the ROC curve (AUC) for the model based on these indexes was 0.801. Compared with the LNM (-) group, the LNM (+) group had a lower overall survival rate at 1 and 2 years (P<0.05). CONCLUSIONS: Clinically relevant detection indexes and pathological P53 levels in patients after EGC radical surgery have a good predictive effect on the occurrence of LNM, which can assist in formulating scientific and reasonable clinical treatment plans.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。